TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04226443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam intravenous injection
Description: The midazolam was prepared as 5 mg midazolam in 20 mL syringe of 5% dextrose water solution (0.25 mg/mL) in both arms. Both groups of patients received an intravenous bolus dose of midazolam was administered before the start of the surgery. In Group 1, continuous infusion of intravenous midazolam was started and in Group 2, intravenous bolus doses of midazolam were administered. The doses were adjusted depending on pain level and sedation level using appropriate scales for monitoring during the surgical time period. The drip rate was adjusted according to pain intensity. The infusion of drugs was discontinued at the end of the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam intravenous injection
Description: The midazolam was prepared as 5 mg midazolam in 20 mL syringe of 5% dextrose water solution (0.25 mg/mL) in both arms. Both groups of patients received an intravenous bolus dose of midazolam was administered before the start of the surgery. In Group 1, continuous infusion of intravenous midazolam was started and in Group 2, intravenous bolus doses of midazolam were administered. The doses were adjusted depending on pain level and sedation level using appropriate scales for monitoring during the surgical time period. The drip rate was adjusted according to pain intensity. The infusion of drugs was discontinued at the end of the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil intravenous bolus dose
Description: A remifentanil infusion was prepared as follows; 0.5 mg remifentanil was added into 100 mL of 0.9% saline at a concentration of 5 μg/mL. The preparation of remifentanil solution and installation of the device was done by an anesthesiologist who was blinded for the study groups. The dose and number of patients that required remifentanil were recorded. The infusion of drugs was discontinued at the end of the procedure. A rescue medication of intravenous remifentanil bolus dose was used as 1 to 3 mL (5 μg or 15 μg) every 5 minutes if necessary for pain scores greater than 3. This infusion was prepared prior to the use during the study and was discontinued at the end of the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil intravenous bolus dose
Description: A remifentanil infusion was prepared as follows; 0.5 mg remifentanil was added into 100 mL of 0.9% saline at a concentration of 5 μg/mL. The preparation of remifentanil solution and installation of the device was done by an anesthesiologist who was blinded for the study groups. The dose and number of patients that required remifentanil were recorded. The infusion of drugs was discontinued at the end of the procedure. A rescue medication of intravenous remifentanil bolus dose was used as 1 to 3 mL (5 μg or 15 μg) every 5 minutes if necessary for pain scores greater than 3. This infusion was prepared prior to the use during the study and was discontinued at the end of the procedure.
Study: NCT00089388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV
Study: NCT04582617

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa Extract
Description: 2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa Extract
Description: 2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa Extract Placebo
Description: Cocoa extract placebo
Study: NCT02794974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical plexus block
Description: ultrasound-guided application of 20ml ropivacaine 0.75%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical plexus block
Description: ultrasound-guided application of 20ml ropivacaine 0.75%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: facial nerve block
Description: ultrasound-guided application of 5ml prilocaine 1%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: facial nerve block
Description: ultrasound-guided application of 5ml prilocaine 1%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perivascular block
Description: ultrasound-guided application of 5ml prilocaine 1%
Study: NCT01029340

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (BAY81-8973)
Description: Single dose of BAY81-8973 crossed over to single dose of Kogenate FS

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Single dose of Kogenate FS crossed over to Single dose of BAY81-8973

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (BAY81-8973)
Description: Participants received IV injections of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia (CS/EP) for 6 months and by Chromogenic Substrate Assay/Adjusted to Label Potency (CS/ADJ) for 6 months, sequence according to randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (BAY81-8973)
Description: Participants received IV injections of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia (CS/EP) for 6 months and by Chromogenic Substrate Assay/Adjusted to Label Potency (CS/ADJ) for 6 months, sequence according to randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (BAY81-8973)
Description: Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
Study: NCT01131195

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab, Paclitaxel
Description: Bevacizumab (10 mg/kg) i.v. is given every two weeks. Paclitaxel (90 mg/m2) i.v. is given on days 1, 8, and 15 of a 4 week cycle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab, Cyclophosphamide, Capecitabine
Description: Bevacizumab (10 mg/kg) i.v. is given every two weeks. Cyclophosphamide (50 mg) and capecitabine (3x 500 mg) p.o. are given daily
Study: NCT01411969

Intervention type: DRUG
Intervention: External Nasal Dilator Strip; 0.05% oxymetazoline chloride
Description: External Nasal Dilator Strip placed above the upper lateral cartilage; 20 minutes after decongestion with 0.05% oxymetazoline chloride applied as an aerosol spray (two times); after decongestion with ENDS.
Study: NCT02668718

Intervention type: RADIATION
Group type: OTHER
Intervention: Adjuvant radiotherapy
Description: The radiation therapy will be given in 37 fractions of 1.8 Gy per day, five days per week. The total dose of radiation will be 66.6 Gy.
Study: NCT00529971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR group
Description: 8-week MBSR group, 3 hours per week plus one all day retreat

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Treatment as usual, which could include medications or psychotherapy
Study: NCT00958139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Permethrin
Description: Permethrin 0.5% treatment of clothing one time

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: water sprayed on clothing one time
Study: NCT02215603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breaking prolonged sitting with physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breaking prolonged sitting with physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breaking prolonged sitting with physical activity
Study: NCT04741724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEDS
Description: An non-invasive intervention. During the intervention, the electrode was placed on the skin stimulated muscle.
Study: NCT03856255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro-Tech Endoscopic Gauge
Description: Use of Micro-Tech Endoscopic Gauge to measure any polyp detected during a screening or surveillance colonoscopy.
Study: NCT03535623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning (RIPC)
Description: RIPC consists of 4 cycles of 5-min ischemia using pneumatic cuff pressure of 200 mmHg and 5-min reperfusion.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-RIPC
Description: Sham-RIPC consists of 4 cycles of 5-min ischemia using pneumatic cuff pressure of \< 10 mmHg and 5-min reperfusion.
Study: NCT03333070

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic - Lactobacillus reuteri
Description: The treated arm will receive 5 drops per day for 48 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo - with no active ingredient
Description: The control arm will receive 5 drops per day for 48 weeks
Study: NCT03064139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCG
Description: Community-based in person group training n mindful walking over 11 sessions in 6-months+ Activity monitor with feedback on activity levels

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SCG
Description: Community-based in person group education in management of knee osteoarthritis (importance of physical activity, weight management, etc.) over 11 sessions in 6 months + Activity monitor with feedback on activity levels
Study: NCT04232735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tool and training
Description: The Source tool aims to assist health care providers with giving evidence based information about treatment outcomes by providing visualizations of personalized predictions of treatment outcomes for different treatments of oesophageal and gastric cancer. These predictions result from recently designed and updated prediction models on the survival, toxicity, complications and health related quality of life of oesophageal and gastric cancer patients.~The training aims to teach participants to inform patients about outcomes of treatment. The training is placed in the context of shared decision making (SDM), following the 4-step model by Stiggelbout et al., 2015.8 The training is provided in small groups (3-6 participants) by an experienced trainer and supported by professional actors. The training aims to address knowledge, attitude and skills.
Study: NCT02574637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab IV Infusion
Description: Brazikumab IV infusion as per protocol specified dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab IV Infusion
Description: Brazikumab IV infusion as per protocol specified dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab IV Infusion
Description: Brazikumab IV infusion as per protocol specified dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab IV Infusion
Description: Brazikumab IV infusion as per protocol specified dosing schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brazikumab IV Infusion
Description: Brazikumab IV infusion as per protocol specified dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab SC Injection
Description: Brazikumab IV infusion as per protocol specified dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab SC Injection
Description: Brazikumab IV infusion as per protocol specified dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab SC Injection
Description: Brazikumab IV infusion as per protocol specified dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab SC Injection
Description: Brazikumab IV infusion as per protocol specified dosing schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brazikumab SC Injection
Description: Brazikumab IV infusion as per protocol specified dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching Brazikumab IV infusion as per protocol specified dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching Brazikumab IV infusion as per protocol specified dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching Brazikumab IV infusion as per protocol specified dosing schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching Brazikumab IV infusion as per protocol specified dosing schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching Brazikumab IV infusion as per protocol specified dosing schedule.
Study: NCT04311086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation (Symplicity Spyral™)
Description: Device: Symplicity Spyral™ multi-electrode renal denervation system. After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
Study: NCT00682266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensity controlled interval training (AIT)
Description: 4 x 4 min intervals at 90% of maximal heart rate, each interval separated by 3 min at 70%, twice a week for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary approach (MTG)
Description: exercise, dietary and psychological advice, twice a month for 12 months
Study: NCT03591445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible Bronchoscopy
Description: Flexible Bronchoscopy
Study: NCT01175902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dorzolamide/timolol
Description: dorzolamide/timolol fixed combination eyedrop, 2 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dorzolamide/timolol
Description: dorzolamide/timolol fixed combination eyedrop, 2 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost
Description: compare with dorzolamide/timolol fixed combination eyedrop one time a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost
Description: compare with dorzolamide/timolol fixed combination eyedrop one time a day
Study: NCT03098836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARN-509
Description: 240 mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARN-509
Description: 240 mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: 1000 mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg orally twice daily (for total daily dose 10 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg orally twice daily (for total daily dose 10 mg)
Study: NCT01420146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zr89-trastuzumab
Description: trastuzumab labelled with zirconium 89 for PET/CT
Study: NCT04189679

Intervention type: OTHER
Intervention: Immune signature in serum associated to the metabolic signature
Description: Immune signature in serum associated to the metabolic signature

Intervention type: OTHER
Intervention: Immune signature in serum associated to the metabolic signature
Description: Immune signature in serum associated to the metabolic signature

Intervention type: GENETIC
Intervention: Meta-genomic signature of intestinal flora
Description: Meta-genomic signature of intestinal flora

Intervention type: GENETIC
Intervention: Meta-genomic signature of intestinal flora
Description: Meta-genomic signature of intestinal flora
Study: NCT02648126

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pure Red Cell Aplasia diagnostic confirmation
Description: Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation by collecting 20 mL of blood in dialysis units.~The samples will be processed, aliquoted and transported to Bio-Manguinhos, where depart periodically (according to the volume of samples) to the reference laboratory Sce Immunologie et d'Hématologie biologiques Hôpital Saint Antoine, where the dosage of antibody will be held anti epoetin alfa
Study: NCT01764074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Sleep Intervention
Description: Participants will meet with a therapist for three sessions to try to improve sleep problems (hypersomnia or insomnia, depending on the problems the participant has).
Study: NCT01887977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI examination
Description: The vocal and nasal tracts from the lips and nostrils to the beginning of the trachea are imaged with Siemens Avanto 1.5T MRI machine using carefully optimized, externally triggered imaging sequences that are synchronized with the rest of the experimental setting. A sound sample, given by the test subject, is recorded simultaneously to obtain a coupled data set: the speech sound and the precise anatomy which produces it.
Study: NCT03067909

Intervention type: OTHER
Intervention: CIED surgery
Study: NCT01463098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 1.0 mg
Description: E2006 1.0 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 2.5 mg
Description: E2006 2.5 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 2.5 mg
Description: E2006 2.5 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 5.0 mg
Description: E2006 5.0 mg (2 capsules of 2.5 mg each).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 10.0 mg
Description: E2006 10.0 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 10.0 mg
Description: E2006 10.0 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 25.0 mg
Description: E2006 25.0 mg (2 capsules of 10 mg each and 2 capsules of 2.5 mg each).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 25.0 mg
Description: E2006 25.0 mg (2 capsules of 10 mg each and 2 capsules of 2.5 mg each).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 50.0 mg
Description: E2006 50.0 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 100 mg
Description: E2006 100 mg (2 capsules of 50 mg each).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 200 mg
Description: E2006 200 mg (4 capsules of 50 mg each).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Description: Zolpidem 10 mg immediate release tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 Matched Placebo or Zolpidem Matched Placebo
Description: E2006-matched placebo capsules or zolpidem-matched placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006 Matched Placebo
Description: E2006-matched placebo capsule.
Study: NCT01792908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: The KT used was Kinesiology Tape® of 5 cm and it was applied according to Kase protocol (Kase K). The first layer of tape consisted of a single strip placed over the anterior talofibular ligament from insertion to origin, with a 50% tension, except the two-centimetre proximal and distal ends, applied with no tension. The same procedure was repeated for the calcaneofibular ligament and posterior talofibular ligament
Study: NCT04582617

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa Extract Placebo
Description: Cocoa extract placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Multivitamin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Multivitamin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin placebo
Description: Multivitamin placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamin placebo
Description: Multivitamin placebo
Study: NCT02395822

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-15
Description: Preparative Regimen:~Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (if \< 4 months from prior transplant, omit day -4 dose)~IL-15 Activated Donor NK Cells:~The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be activated by overnight incubation with10 ng/ml IL-15 under GMP conditions and infused on day 0.~IL-15 to Facilitate NK Cell Survival and Expansion:~IL-15 at 2 mcg/kg subcutaneously (SC) beginning day +1, once a day for 5 days followed by a 2 day rest, and then once a day for 5 days for 10 doses total
Study: NCT02494024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose C2N-8E12
Description: C2N-8E12 is a humanized recombinant anti-human tau antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose C2N-8E12
Description: C2N-8E12 is a humanized recombinant anti-human tau antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose C2N-8E12
Description: C2N-8E12 is a humanized recombinant anti-human tau antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose C2N-8E12
Description: C2N-8E12 is a humanized recombinant anti-human tau antibody.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single dose placebo
Description: Subjects will be block randomized to receive a single dose of C2N-8E12 or placebo in two blocks of 4 subjects (3:1, C2N-8E12:placebo) per cohort.
Study: NCT02819128

Intervention type: OTHER
Group type: OTHER
Intervention: Swabs skin, pharyngeal, and blood sample
Description: Collection of one blood sample with a volume of 10 mL (2 tubes of blood 5 mL ) and 2 swabs ( throat and skin ).

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of body lice
Description: For the subjects infested with body lice , if they want, their underwear will be recovered and sent to the laboratory to measure the resistance to permethrin.